Resultados de la búsqueda 251-260 of 7366 for egfr
placebo in combination with ado-trastuzumab emtansine (TTT-DM1) in patients with stage II-III HER2+ breast cancer with residual disease post-neoadjuvant ...
Almost one-half million people suffer venous thromboembolism annually in the United States, and one-third die from this disease.
The purpose of this study is to build a National Registry of individuals with one of the group of primary immune deficiency diseases.
Effective treatments for recurrent gynecological cancer are lacking, and there is a need for novel therapeutic options. One of the barriers to improving ...
The purpose of this registry is to collect and maintain samples of breast tissue from women and men undergoing surgery for a breast related concern at Mayo ...
The purpose of this study is to study the handling of ovarian tissue, cryopreservation technology, and oocyte maturation for female pediatric cancer patients ...
Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The primary objective of this proposal is to develop a Thoracic Specimen Registry at Mayo Clinic ...
Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...
Many of the current imaging tests we have for prostate cancer are problematic in their ability to distinguish cancerous from non-cancerous prostate tissue. This ...
Hepatic encephalopathy may be caused by injury to the liver, cancer or a chronic liver disease that results in liver failure, such as cirrhosis. Hepatic ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?